The earnings call revealed a mixed performance with notable achievements in product sales growth and strategic partnerships, but also significant challenges in revenue decline and increased competition affecting key products like Glucagon and Epinephrine. Operational efficiency measures and pipeline progress provide optimism for the future, but current financial pressures and competition present ongoing challenges.

Company Guidance -

Q3 2025

During Amphastar Pharmaceuticals' first quarter earnings call for fiscal year 2025, the management provided guidance on several key metrics and strategic initiatives. The company reported net revenues of $170.5 million, marking a 1% decrease from the previous year. BAQSIMI achieved sales of $38.3 million in the first quarter, nearly matching the combined sales of this product by Lilly and Amphastar from the prior year. Primatene MIST sales rose 20% to $29 million, driven by increased unit volumes and expanded physician outreach. Despite competitive pressures leading to a 27% decline in Glucagon injection sales to $20.8 million and a 29% decrease in Epinephrine sales to $18.6 million, Amphastar remains optimistic about its long-term growth prospects. The company continues to focus on expanding its branded product portfolio and anticipates that BAQSIMI and Primatene MIST will drive revenue growth throughout 2025. Furthermore, Amphastar is actively pursuing several pipeline opportunities, with an emphasis on capturing near-term growth through strategic FDA filings and responses. The company is also preparing for potential impacts from tariff policies but believes its U.S.-based manufacturing operations position it favorably.

Drug Shortage Assistance Award

Amphastar received the Drug Shortage Assistance Award from the USFDA for its efforts in preventing critical drug shortages.

BAQSIMI Sales Growth

BAQSIMI sales grew 177% to $38.4 million compared to $13.8 million in the prior year period, reflecting Amphastar's full control over distribution.

Primatene MIST Sales Increase

Sales of Primatene MIST increased by 20% to $29 million, attributed to increased unit volumes and demand.

Pipeline Progress

The FDA accepted a Biologics License Application for AMP-004, with a BsUFA goal date in Q1 2026, marking a milestone in expanding biosimilar insulin offerings.

Operational Efficiency Measures

Amphastar is implementing cost-efficient strategies to combat margin pressures and enhance operational effectiveness.

Amphastar Pharmaceuticals (AMPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AMPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	0.85 / -	0.96	―	―	―
Aug 07, 2025	2025 (Q2)	0.74 / 0.85	0.94	-9.57% (-0.09)
May 07, 2025	2025 (Q1)	0.69 / 0.74	1.04	-28.85% (-0.30)
Feb 27, 2025	2024 (Q4)	0.94 / 0.92	0.88	4.55% (+0.04)
Nov 06, 2024	2024 (Q3)	0.99 / 0.96	1.15	-16.52% (-0.19)
Aug 07, 2024	2024 (Q2)	0.77 / 0.94	0.65	44.62% (+0.29)
May 08, 2024	2024 (Q1)	0.77 / 1.04	0.62	67.74% (+0.42)
Feb 28, 2024	2023 (Q4)	0.91 / 0.88	0.73	20.55% (+0.15)
Nov 08, 2023	2023 (Q3)	0.69 / 1.15	0.38	202.63% (+0.77)
Aug 08, 2023	2023 (Q2)	0.56 / 0.65	0.39	66.67% (+0.26)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AMPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$21.62	―	―
May 07, 2025	$24.43	$24.65	+0.90%
Feb 27, 2025	$31.49	$28.43	-9.72%
Nov 06, 2024	$53.40	$46.09	-13.69%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Amphastar Pharmaceuticals (AMPH) report earnings?

Amphastar Pharmaceuticals (AMPH) is schdueled to report earning on Nov 10, 2025, After Close (Confirmed).

What is Amphastar Pharmaceuticals (AMPH) earnings time?

Amphastar Pharmaceuticals (AMPH) earnings time is at Nov 10, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AMPH EPS forecast?

AMPH EPS forecast for the fiscal quarter 2025 (Q3) is 0.86.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing